title: Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.
abstract: The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA wchen@medicine.umaryland.edu kkotloff@medicine.umaryland.edu.
authors.forename: Wilbur H
authors.initials: WH
authors.lastname: Chen
authors.affiliation: Group Health Research Institute, Seattle, Washington, USA.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Jackson
authors.affiliation: Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: Edwards
authors.affiliation: Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Keitel
authors.affiliation: EMMES Corporation, Rockville, Maryland, USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Hill
authors.affiliation: Southern Research, Birmingham, Alabama, USA.
authors.forename: Diana L
authors.initials: DL
authors.lastname: Noah
authors.affiliation: Vanderbilt Vaccine Research Program, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
authors.forename: C Buddy
authors.initials: CB
authors.lastname: Creech
authors.affiliation: Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Shital M
authors.initials: SM
authors.lastname: Patel
authors.affiliation: EMMES Corporation, Rockville, Maryland, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Mangal
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA wchen@medicine.umaryland.edu kkotloff@medicine.umaryland.edu.
authors.forename: Karen L
authors.initials: KL
authors.lastname: Kotloff
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000009:adverse effects; D055815:Young Adult; D024502:alpha-Tocopherol / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004338:Drug Combinations; D007252:Influenza Vaccines; D011136:Polysorbates; D013185:Squalene; C550253:AS03 adjuvant; D024502:alpha-Tocopherol